Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I of course am now leery of DABLOOD- But, will wait and see what they may have to offer in the future.
FDA has results of their test and here are some other results I found - Excel Document - Go to Clinical Performance tab on bottom and search DABLOOD
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjlq_yqpoztAhVQCuwKHU62Dik4KBAWMAB6BAgDEAI&url=https%3A%2F%2Fwww.medrxiv.org%2Fhighwire%2Ffilestream%2F97421%2Ffield_highwire_adjunct_files%2F0%2F2020.09.16.20195917-1.xlsx&usg=AOvVaw2xcYaewUMN-MYqGjWuaIjw
This was interesting from FDA yesterday as well- not sure on accuracy or how many they could produce.....I will look into when I have more time.... Will the new DABLOOD kit compare?????? What exactly are they looking to test for on the advanced DABLOOD kit? Anyone know any more on this?
Agree, Illumina knows this as well and is buying GRAIL back at a substantial price.
https://www.biopharmadive.com/news/illumina-buy-grail-cancer-screening/585606/
Illumina has agreed to acquire Grail in an $8 billion deal that could establish the sequencing giant as a leading player in the growing race to use blood-based tests known as liquid biopsies to catch cancers early.
I will start this off
PRODUCTS IN DEVELOPMENT
Background - Molecular Diagnostics
We believe that advances in the emerging field of molecular diagnostics will improve our ability to determine which patients are subject to a greater risk of developing disease, and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate drug at the optimal dose. Every week, disease-linked genetic variations are being discovered. Genetic tests are now available for over 4,000 diseases and conditions. Once only a niche market of the in vitro diagnostics industry, molecular genetic testing is playing an increasingly valuable and prominent role in health care. In all areas of medicine, DNA based tests are assisting clinicians in the management of diseases and in the selection of treatment by enabling earlier diagnosis or prediction of disease risk years before symptoms occur. The domestic market for molecular diagnostics is a multi-billion dollar market and is the strongest segment of the entire in vitro diagnostics market, growing at an annual average rate of over 20%.
We believe there are significant diagnostic market opportunities for disease identification. Simple, non-invasive diagnostic, prognostic, and predictive tests do not exist for many of the major diseases affecting women and men. Unlike traditional medical tests, molecular genetic tests are often proprietary, high-margin tests that can move quickly from discovery to commercialization, particularly in a CAP accredited and CLIA certified laboratory as a Laboratory Developed Test (LDT), for which the FDA currently exercises enforcement discretion.
In general, accurate early detection, disease identification and assessment of health status can translate into reduced morbidity, improved quality of life and reduced treatment costs associated with detection and treatment of disease during later stages.
Conclusions: The overlap between DDR genes responding to ATRN-119 and those mutated in endometriosis-associated cancer suggest that genetic markers underlying response and resistance will be critical to extend the use of these drugs while increasing efficacy and minimizing toxicities. Furthermore, our data support the inclusion of endometriosis-associated cancer patients in planned ATRN-119 clinical trials.
This or something bigger???
Conclusions
Deletions significantly differential in prevalence between these groups were observed in several regions of very common known CNV, which may have plausible link to key theories on reproductive success and evolution. The variants observed on the first two regions (chr7 & 14) involved variant transcripts of the T-cell receptor-g and -a respectively. On chromosome 11 the deletions involved the 52N1 and 52N5 families of olfactory receptor genes. Both the immune response and olfactory perceptions have been suggested to be involved with the evolution of eutherian mammalian reproduction and fertility in humans.
Here is what I see
Exhibit 99.1 PRPH today
Mr. Karkus added, “If ProPhase Labs is able to generate a net margin of just $30 per COVID-19 test (which we believe is conservative based on current industry dynamics), for each 1,000 tests processed per day, our lab could generate approximately $30,000 in net operating income. If these levels can be attained and sustained, just on the basis of processing 1,000 units a day, five days per week, we would project approximately $7.5 million in annualized pre-tax operating income. However, we expect our lab to have capacity to process many more test kits than just 1,000 per day. Our current goal is to have a run rate of at least 4,000 units processed per day, on average, by the end of the first quarter of 2021. We also anticipate processing up to seven days per week.”
It would have been amazing if they had 50 million in sales. But, reality is it was 1.2 million, Not sure when they started the testing. Did they start two weeks prior to end of Q or run the whole Q?
However- PRPH gave an estimate of $30 per test today-
so let's try a simple math approach on amount of test PRED potentially did...
1.2 million divided by $30
40K test
That does not sound so crazy after reading the other post.
Interesting read- PRED
https://www.utahbusiness.com/biotech-companies-pandemic/
There seems to be some legitimacy lost for some, if there ever was any. Have a great rest of the weekend. Interesting stuff going on and waiting to see if PRED is part of it or not.
Looking forward to the first 2021 Q for PRED.
Morman brotherhood, pacific brotherhood and LDS? What are you talking about? Who is Han? Is the the marketing guy for PRED or somebody else? Not me buddy, I am Brian. I am here because I am a shareholder and tired of all the shenanigans going on. So I have attempted to find truth. You have shown me on several occasions that is not your goal- truth is hard for some.
Are you saying you sold RMS to PRED?
What did you advise?
Per your admission you were an employee at PRED. I think this alone would warrant a deeper dive into your doings at PRED. We’re you still employed when PRED had the break in?
I quote
“St George Saturday, 11/07/20 07:33:05 AM
Re: None 0
Post # of 49154
Yes IB I’m a major shareholder, was involved with and working for PRED at one point and got tired of all the lies and didn’t want to risk my provider reputation in our community, I don’t know Merle personally but I observed his actions and reputation and quickly came to the conclusion, along with other board and advisory board members, that he should be removed and distanced from PRED, he was caught selling restricted shares, as was Ward around May of 2019, not to mention he pushes three or four penny stocks at the same time. I don’t know the other person you mentioned. If Sorrentino knows Merle then Sorrentino’s character just got knocked down several notches. “
So did Rick sell RMT as garbage when he sold it to PRED. Shareholders like myself would like to know.
Your post says otherwise ———no one knew but you..were you not an insider of PRED at that time?
I quote
“St George Tuesday, 05/19/20 11:19:08 AM
Re: None 0
Post # of 49152
Just heard PRED cut two new videos highlighting how to use Assurance AB, which is a great indication that the test is rolling out! As soon as they’re posted to PRED website I’m sure Brian will share the links! Good signs!”
Any idea why DR. Obray left? You seem to have good knowledge on PRED from your previous post and I believe you said you bought product from them last year. Also, you tipped us off to the new video last year from PRED before they released it public if I remember correctly.I may be wrong on that detail....
Did Obray slip away after hit job by HB?
EXHIBIT A
ARTICLES OF MERGER
[To be completed]
RMT DISCLOSURE SCHEDULE
Schedule 3.7Personal Property
•Data License Agreement dated May _, 2018 between Southwest Spine and Pain Care Specialists, LLC and Regenerative Medical Technologies, Inc.
•Draft Provisional Patent Application -Systems and Methods for Linking and Storing Biologics.
•Cellsure business model, methods and protocols to collect birthing tissue, DNA samples and electronic medical records online or on mobile app.
•Patient Registry business model, methods and protocols to collect clinical outcomes and electronic medical records online or on mobile app.
•DNA sample business model, methods and protocols to collect DNA samples and electronic medical records online or on mobile app.
•Bone Marrow Aspirate Kit - draft product design and methodology.
•Large Joint Injection Kit-draft product design and methodology.
•Degenerative Disk Disease (DDD) and Post-Microdiscectomy Injection Kit - draft product design and methodology.
•Allogenic Stem Cell Product for DOD-draft product design and preliminary clinical trial methodology
•Allogenic Stem Cell Product for Autism and CP - draft product design and preliminary clinical trial methodology
•Allogenic Stem Cell Product for Facet Joint - draft product design and preliminary clinical trial methodology
26
•Allogenic Stem Cell Product for IV Treatment of Opioid Addiction - draft product design and preliminary clinical trial methodology
•Clinical Trial protocol know-how (draft design for knee arthritis, trochanteric bursitis, plantar fasciitis, discogenic back pain, facet joint pain).
Schedule 3.13 Contractual and Other Obligations
•See Schedule 3.7 above.
Schedule 4.4
There are no pending or threatened actions except for:
(i)a lawsuit filed by Robert Greeen, Troy Menlove and TRJ, LLC in the Third Judicial District Court against Jack Turner, Buyer and Predictive Biotech, Inc. in July 2018 alleging, among other things, that cash and stock compensation is due to plaintiffs and Buyer disputes such claims; and
(ii)there is a dispute between Buyer and Mike Schramm, Buyer's former patent agent, whereby Mr. Schramm alleges he is owed common stock as compensation for intellectual property transferred to Buyer and/or its affiliates and for work performed. Buyer believes Mr. Schramm has been fully compensated for all transferred intellectual property and work performed.
Anyone know why Dr. Obray left the company??? He seemed to be doing a lot last year....
SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent precision therapeutic intervention, announces its wholly owned subsidiary Predictive Laboratories has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain.
The primary objective of the IRB study is to conduct genetic research related to healthcare advancement in the diagnosis, treatment and prevention of conditions causing chronic pain. The first 200 participants have volunteered for the study by submitting their DNA samples to the Predictive Biorepository and by reporting detailed medical information through their healthcare providers.
Looks like nothing based on the filing...Did that guy in St. George make off like a bandit on this deal?
Impairment of Trade Secrets
As of June 30, 2020, the Company identified indicators of impairment related to the assets acquired with Regenerative Medical Technologies, Inc. (see Note 2). Specifically, development of the assets acquired has proceeded significantly more slowly than originally planned due to the departure of key personnel and related difficulties in obtaining patient consent required to use the acquired assets in the Company's research activities. The Company determined the fair value of the assets acquired to be $334,000 using the cost to recreate method, which resulted in an impairment charge of $10,041,556. This valuation approach uses inputs that qualify as Level 3 in the fair value hierarchy. The impairment charge is included in loss on impairment in the consolidated statement of operations. The impaired assets and the related impairment charge is included in the Diagnostics and Therapeutics segment.
NOTE 2 BUSINESS COMBINATIONS AND EQUITY METHOD INVESTMENTS
Regenerative Medical Technologies, Inc.
On December 19, 2018, the Company completed an asset acquisition via a merger with the stockholders of Regenerative Medical Technologies, Inc. ("RMT"), a Utah corporation. The Company acquired RMT for 10,000,000 shares of common stock. RMT holds various assets including (i) models, methods and protocols for collection of birthing tissue and DNA samples, (ii) patient registry models, methods and protocols to collect clinical outcomes and electronic medical records, and (iii) designs and methodologies relating to many initiatives that are complementary to anticipated product offerings and ongoing research, and (iv) other assets.
The fair value of consideration paid was determined based on our stock price of $0.92 on the date of acquisition. In addition, the Company recognized a deferred tax liability of $3,066,667 related to the differences between book and tax basis arising from the acquisition, resulting in a total purchase price of $12,266,667. The Company determined that the assets acquired qualify for treatment as trade secrets within industry. The trade secrets will be amortized over an estimated useful life of 10 years.
Intangible Assets and Other Long-Lived Assets
As of June 30, 2020, the Company had identified indicators of impairment for certain of its long-lived assets for certain of its long-lived assets and performed an impairment test related to those long-lived assets. An impairment charge of $10,041,556 was recorded related to assets acquired with Regenerative Medical Technologies, Inc. (see Note 5). There were no impairments for the year ended June 30, 2019.
Impairment of Trade Secrets
As of June 30, 2020, the Company identified indicators of impairment related to the assets acquired with Regenerative Medical Technologies, Inc. (see Note 2). Specifically, development of the assets acquired has proceeded significantly more slowly than originally planned due to the departure of key personnel and related difficulties in obtaining patient consent required to use the acquired assets in the Company's research activities. The Company determined the fair value of the assets acquired to be $334,000 using the cost to recreate method, which resulted in an impairment charge of $10,041,556. This valuation approach uses inputs that qualify as Level 3 in the fair value hierarchy. The impairment charge is included in loss on impairment in the consolidated statement of operations. The impaired assets and the related impairment charge is included in the Diagnostics and Therapeutics segment.
Probably need to call Atrin then with all of your knowledge of inside information.
Wow....sore spot g for PRED and it’s employee’s.... tisk tisk
Did you happen to see illumina on page 2 right side?
TA Yap has received research funding from AstraZeneca, Vertex Pharmaceuticals and Clearbridge Biomedics. He is also an advisory board member for AstraZeneca, Pfizer Inc, EMD Serono, Clovis, Bristol-Myers Squibb, Ignyta, Roche, Janssen Pharmaceuticals, Atrin and Aduro and has received travel support from AstraZeneca, Bristol-Myers Squibb, Merck Sharp Dohme, Vertex Pharmaceuticals, GlaxoSmithKline, EMD Serono and Tesaro.
Link to a Yap
https://faculty.mdanderson.org/profiles/timothy_yap.html
Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR and PARP inhibitors, as well as the development of novel immunotherapeutics. His laboratory interests included the development of patient-derived xenografts (PDXs) and circulating plasma DNA as predictive biomarkers of response for novel targeted agents and immunotherapies in clinical trials.
This was an article from Timothy Yap a few years ago...I am sure he was just a nobody.....
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2018.1479740
The goal of this collaboration is to develop actionable predictive molecular and companion diagnostics and therapeutics for these common disorders and related cancers.
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e18000
Who was involved in this study
Oren Gilad, Dansu Li, Erin George, Rakesh Chettier, Fiona Simpkins, Kenneth Ward, Eric J Brown
Atrin Pharmaceuticals, Doylestown, PA; Perelman School of Medicine, Philadelphia, PA; Predictive Laboratories, Salt Lake City, UT; University of Pennsylvania School of Medicine, Philadelphia, PA
Interesting read regarding exosomes if you have interest. Some of the new PRED literature talks more on the naturally occurring exosomes.
Not trying to say this has anything to do specific to PRED- shows the work progression into exosomes happening in this field.
https://www.nature.com/articles/s41587-020-0725-7.pdf
Not that any of you dipshits would say anything good about it, you know who I am talking about....I shared this because I think Atrin is on a path to success- who knows minus the published paper earlier in the year if they are still working with PRED. Not here to prove anything to anyone.
Arthur, not sure who that is? I think of myself more as Brian, since that is my legal name. You should as well.
Do you think any of this is relevant to today’s PRED outlook? Was this posted to soon and is now closer to fruition?
Mack, I believe, had good insight in this post. Whatever happened between them and PRED is in the history books or is it?
Follow up here for the more thorough explanation
https://www.investor.gov/introduction-investing/general-resources/news-alerts/alerts-bulletins/investor-bulletins-51
Real simple buzzard- they are the “legal” shares in short position at time of reporting date.
Simply put, someone has to buy those back and I say we make that really expensive for them. That is fact unless PRED goes bankrupt...they would get off the hook for free in that case.
Some still stay the real crime was all the naked shorting- who knows. I like to track numbers though.
Updated
History of FINRA short interest reported
2020-10-30 357,878
2020-10-15 384,425
2020-09-30 359,618
2020-09-15 360,183
2020-08-31 363,099
2020-08-15 360,082
2020-07-31 362,568
2020-07-15 434,933
2020-06-30 440,897
2020-06-15 432,664
2020-05-29 633,652
2020-05-15 656,356
2020-04-30 437,038
2020-04-15 946,303
2020-03-31 773,513
2020-03-13 193,788
nice sells today.
New report will be out in a few days
History of FINRA short interest reported
2020-10-15 384,425
2020-09-30 359,618
2020-09-15 360,183
2020-08-31 363,099
2020-08-15 360,082
2020-07-31 362,568
2020-07-15 434,933
2020-06-30 440,897
2020-06-15 432,664
2020-05-29 633,652
2020-05-15 656,356
2020-04-30 437,038
2020-04-15 946,303
2020-03-31 773,513
2020-03-13 193,788